Chapters

Transcript

Video

Are we entering a new therapeutic era for NCFBE with agents like brensocatib, recently approved to target neutrophil-driven inflammation central to the disease’s pathobiology?


Created by

CMEducation Resources iQ&A Bronchiectasis (NCFBE) Pulmonary Medicine Intelligence Zone

Presenter

Professor James Chalmers

Professor James Chalmers

Professor (Clinical), Molecular and Clinical Medicine
School of Medicine
University of Dundee School of Medicine
Dundee, Scotland, United Kingdom

Professor (Clinical), Molecular and Clinical Medicine
School of Medicine
University of Dundee School of Medicine
Dundee, Scotland, United Kingdom